ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
ISO 9001:2015 Certified WHO-GMP PCD Pharma Franchise Company in India300+ Products Monopoly Rights Pan India DistributionCall us: +91-86533 91199
Product List
Home / ARPOD-CV DRY SYP
ARPOD-CV DRY SYP

MISONET DP

Product Packing: 5X30

Product Composition: doxylamine succinate 10mg+ pyridoxine hydrochloride 10 mg + folic acid 2.5 mg

Product Price: MRP :

MISONET MD 4 Mouth Dissolving Tablets

Ondansetron 4 mg Mouth Dissolving Tablets

MISONET MD 4 is a prescription antiemetic formulation containing Ondansetron 4 mg in a mouth dissolving tablet dosage form. Ondansetron is a selective 5-HT3 receptor antagonist used for prevention and treatment of nausea and vomiting in approved clinical settings.

Ondansetron blocks serotonin 5-HT3 receptors involved in triggering the vomiting reflex. Treatment selection, dose and duration depend on the clinical situation and should follow the approved product label and qualified medical advice.

Composition

Each mouth dissolving tablet contains:

·         Ondansetron - 4 mg

·         Excipients - q.s.

 

Dosage form: Mouth Dissolving (MD) Tablet

Pack size: 10 x 10 tablets

Uses of MISONET MD 4

MISONET MD 4 may be prescribed for prevention or treatment of nausea and vomiting in selected situations where Ondansetron is approved and clinically appropriate.

·         Prevention and treatment of nausea and vomiting associated with selected medical treatments

·         Management of postoperative nausea and vomiting according to approved prescribing information

·         Antiemetic support in other approved clinical settings as determined by the treating clinician

·         Convenient mouth dissolving dosage form for patients where this formulation is considered appropriate

Persistent or severe vomiting can lead to dehydration and may indicate an underlying condition requiring medical assessment.

How MISONET MD 4 Works

MISONET MD 4 contains Ondansetron, a selective serotonin 5-HT3 receptor antagonist:

5-HT3 receptor blockade: Ondansetron blocks serotonin 5-HT3 receptors in pathways involved in nausea and vomiting.

Antiemetic action: Blocking these receptors helps reduce activation of the vomiting reflex in approved clinical settings.

Peripheral and central action: 5-HT3 receptors involved in emesis are present in both gastrointestinal vagal pathways and central nervous system pathways.

Clinical response depends on the cause of nausea or vomiting, dose, timing and individual patient factors.

Dose selection and treatment duration must follow the approved product label and prescribing clinician's advice.

 

Dosage and Direction for Use

Use MISONET MD 4 exactly as prescribed. Dose and timing vary according to the indication, age, clinical setting, liver function and other patient factors.

Use the mouth dissolving tablet according to the approved pack instructions and the prescriber's directions; handle and administer the tablet as directed for this dosage form.

Do not exceed the prescribed dose or repeat doses more frequently than advised.

Patients with significant hepatic impairment or other relevant risk factors may require individualized dosing according to approved prescribing information.

Possible Side Effects

Possible unwanted effects may include:

·         Headache

·         Constipation, flushing or a sensation of warmth

·         Dizziness or other mild symptoms in some individuals

·         Ondansetron can rarely affect cardiac electrical conduction, including QT-interval prolongation, particularly in susceptible patients

·         Seek urgent medical attention for fainting, significant palpitations, severe allergic symptoms, breathing difficulty or other serious reactions.

Persistent or troublesome adverse effects should be discussed with the treating healthcare professional.

Precautions and Contraindications

Before using MISONET MD 4, the prescriber should review allergy history, heart rhythm risk, electrolyte status, liver function and concomitant medicines. Important precautions include:

·         Do not use in patients with known hypersensitivity to Ondansetron or formulation ingredients.

·         Concomitant use with apomorphine is generally contraindicated because severe hypotension and loss of consciousness have been reported.

·         Use caution in patients with congenital long-QT syndrome, heart rhythm disorders, heart failure, bradyarrhythmias or electrolyte abnormalities.

·         Medicines that prolong the QT interval or alter electrolytes may increase cardiac risk and require professional review.

·         Serotonin syndrome has been reported, particularly when Ondansetron is used with other serotonergic medicines; seek medical advice for concerning symptoms.

·         Pregnancy, breastfeeding, children, older adults and patients with significant liver or cardiac conditions require individualized professional guidance.

·         Keep out of reach of children and store according to the approved pack instructions.

·         Drug Interaction Considerations

·         Important interaction considerations include apomorphine, serotonergic medicines and drugs that prolong the QT interval or affect electrolyte balance. Some enzyme-inducing medicines may also alter Ondansetron exposure.

·         Patients should provide the prescriber with a complete list of prescription medicines, OTC products and supplements before starting treatment.

Business Growth Opportunity with MISONET MD 4

MISONET MD 4 offers pharmaceutical distributors and healthcare entrepreneurs an opportunity to add an Ondansetron 4 mg mouth dissolving antiemetic tablet to their prescription product portfolio.

Antiemetic therapy is used across multiple medically supervised settings. Promotion should remain strictly consistent with approved product information, prescription status and applicable pharmaceutical regulations.

 

Key Business Advantages

·         Single-ingredient antiemetic formulation

·         Ondansetron 4 mg

·         Selective 5-HT3 receptor antagonist

·         Convenient mouth dissolving tablet dosage form

·         Suitable addition to gastroenterology, general medicine and supportive-care prescription portfolios

·         Opportunity for ethical promotion through appropriate healthcare channels

PCD Pharma Franchise Opportunity for MISONET MD 4

Ethics Medinova Private Limited offers PCD Pharma Franchise opportunities for MISONET MD 4 in selected territories across India, subject to availability, applicable regulations and mutually agreed business terms.

Franchise partners may benefit from the company's product portfolio, promotional support, supply coordination and business assistance.

 

Franchise Support May Include

·         Monopoly-based territory opportunities, subject to availability

·         Promotional materials and visual aids

·         Product information and marketing support

·         Reliable supply coordination

·         Access to a growing pharmaceutical product portfolio

·         Professional partner assistance

Partner with Ethics Medinova to explore PCD Pharma Franchise opportunities for MISONET MD 4 and other quality-focused healthcare products.

Third-Party Manufacturing Support for Ondansetron 4 mg Mouth Dissolving Tablets

Ethics Medinova also supports eligible businesses exploring third-party manufacturing of formulations similar to MISONET MD 4 under their own brand, subject to applicable licensing, prescription-drug, regulatory and manufacturing requirements.

Our third-party manufacturing support may include:

·         Customized product and pack requirements, subject to regulatory feasibility

·         Private-label manufacturing opportunities

·         Customized packaging and branding support

·         Product label and pack configuration assistance

·         Manufacturing coordination through suitable licensed facilities

·         Support for documentation and applicable regulatory requirements

This service may be suitable for eligible pharmaceutical companies and healthcare brands seeking to expand an antiemetic prescription product portfolio.

Frequently Asked Questions About MISONET MD 4

1. What is MISONET MD 4?

MISONET MD 4 is a mouth dissolving tablet formulation containing Ondansetron 4 mg.

2. What is MISONET MD 4 used for?

It may be prescribed for prevention or treatment of nausea and vomiting in approved clinical settings where Ondansetron is considered appropriate.

3. How should MISONET MD 4 be taken?

Use MISONET MD 4 exactly according to the approved mouth dissolving tablet instructions and as directed by a qualified healthcare professional.

4. What are common side effects of Ondansetron?

Headache and constipation are among the commonly reported effects. Other reactions can occur and should be discussed with a healthcare professional if persistent.

5. Are there important heart-related precautions?

Yes. Ondansetron can prolong the QT interval in susceptible patients. Heart rhythm disorders, electrolyte abnormalities and other QT-prolonging medicines require professional assessment.

6. Can MISONET MD 4 be used with all medicines?

No. Apomorphine is an important contraindicated combination, and serotonergic or QT-prolonging medicines may require special caution. The prescriber should review all current medicines.

7. Is a PCD Pharma Franchise available for MISONET MD 4?

Yes. Ethics Medinova offers PCD Pharma Franchise opportunities for selected products and territories, subject to availability, applicable regulations and mutually agreed terms.

8. Can this formulation be manufactured under my own brand?

Eligible businesses interested in a similar Ondansetron 4 mg mouth dissolving tablet may explore third-party manufacturing and private-label support with Ethics Medinova, subject to applicable licensing and regulatory requirements.

Disclaimer

MISONET MD 4 product information in this document is for general professional and business information. Exact approved indications, dosage, contraindications, warnings, interactions, administration instructions, monitoring requirements, duration of use, excipients and regulatory status must be verified against the current approved product label and applicable prescribing information before prescribing, dispensing, use or promotion. This document is not a substitute for professional medical advice.

Contact